Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Krystal Biotech (KRYS) Amortizatization of Intangibles (2023 - 2025)

Krystal Biotech's Amortizatization of Intangibles history spans 3 years, with the latest figure at $200000.0 for Q4 2025.

  • For Q4 2025, Amortizatization of Intangibles rose 4.71% year-over-year to $200000.0; the TTM value through Dec 2025 reached $827000.0, up 10.71%, while the annual FY2025 figure was $827000.0, 10.71% up from the prior year.
  • Amortizatization of Intangibles for Q4 2025 was $200000.0 at Krystal Biotech, down from $209000.0 in the prior quarter.
  • Across five years, Amortizatization of Intangibles topped out at $233000.0 in Q4 2023 and bottomed at $182000.0 in Q1 2024.
  • The 3-year median for Amortizatization of Intangibles is $204500.0 (2025), against an average of $206500.0.
  • The largest annual shift saw Amortizatization of Intangibles decreased 18.26% in 2024 before it grew 23.08% in 2025.
  • A 3-year view of Amortizatization of Intangibles shows it stood at $233000.0 in 2023, then fell by 18.03% to $191000.0 in 2024, then grew by 4.71% to $200000.0 in 2025.
  • Per Business Quant, the three most recent readings for KRYS's Amortizatization of Intangibles are $200000.0 (Q4 2025), $209000.0 (Q3 2025), and $194000.0 (Q2 2025).